| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
| Targets |
p-Synephrine targets adrenergic receptors, particularly the β3-adrenoceptor. It is an adrenergic receptor agonist with preferential binding to α-1 and β-3 adrenergic receptors. The compound also activates TAAR-1 receptors and 5-HT receptors. Compared to ephedrine and m-synephrine, p-synephrine exhibits weaker binding affinity for α-1, α-2, β-1, and β-2 adrenergic receptors at commonly used doses and does not demonstrate significant sympathomimetic activity. p-Synephrine acts mainly via the β3 adrenoceptor.
|
|---|---|
| ln Vitro |
In vitro, p-Synephrine has been studied for its effects on adrenergic receptor signaling, thermogenesis, and lipolysis. It acts as a positive inotrope, activating adrenergic receptors with partial selectivity for α-adrenergic receptors. The compound suppresses lipopolysaccharide-induced acute lung injury by inhibition of the NF-κB signaling pathway. Its effects on lipid metabolism and energy expenditure have been characterized in various cell models. Studies have examined its receptor binding profile and downstream signaling pathways.
|
| ln Vivo |
In vivo, p-Synephrine is commonly used in research investigating thermogenesis, lipolysis, and cardiovascular modulation. It has been studied for its effects on metabolic rate, fat oxidation, and cardiovascular function. The compound's ability to activate β3-adrenergic receptors supports its role in promoting lipolysis and energy expenditure. Studies have examined its effects on body weight, metabolic parameters, and cardiovascular responses in animal models. Its anti-inflammatory effects have been demonstrated in models of acute lung injury.
|
| Enzyme Assay |
In cell-free biochemical assays, p-Synephrine is evaluated for its binding affinity to adrenergic receptors. Radioligand displacement studies using membrane preparations from cells expressing recombinant receptors are used to determine the compound's binding affinity for α-1, α-2, β-1, β-2, and β-3 adrenergic receptors. Its purity (>97%) and molecular weight (167.21 g/mol) are characterized using analytical techniques. These assays confirm the compound's mechanism as an adrenergic receptor agonist with preferential β3 activity.
|
| Cell Assay |
Cellular assays for p-Synephrine involve evaluating its agonist activity at adrenergic receptors in various cell lines. The compound's ability to activate β3-adrenergic receptors and stimulate lipolysis is assessed in adipocyte cultures. Its effects on cAMP accumulation and downstream signaling are measured. The compound's anti-inflammatory effects are evaluated in macrophage and lung epithelial cell models. Its effects on cardiovascular function are studied in cardiomyocyte and vascular smooth muscle cell cultures.
|
| Animal Protocol |
Animal models for p-Synephrine include models of obesity, metabolic syndrome, inflammation, and cardiovascular disease. The compound is typically administered orally or via injection. Studies have examined its effects on body weight, fat mass, metabolic rate, and inflammatory markers. Its anti-inflammatory effects have been evaluated in models of acute lung injury. Its cardiovascular effects have been studied in models of blood pressure and heart rate regulation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for p-Synephrine show that the compound has a molecular weight of 167.21 g/mol with a molecular formula of C9H13NO2. The CAS number is 614-35-7. The compound is soluble in water and organic solvents. It should be stored under appropriate conditions to maintain stability. Standard handling procedures for natural alkaloid research compounds apply.
|
| Toxicity/Toxicokinetics |
The toxicity profile of p-Synephrine indicates that it is a much weaker adrenergic agonist than m-synephrine. As a natural stimulant, it is considered to have a relatively favorable safety profile. Standard safety precautions for handling research chemicals apply. The compound is for research use only and not for human use. No significant toxicity has been reported at research doses.
|
| Additional Infomation |
D-Synephrine is the D-enantiomer of synephrine and is the conjugate base of D-synephrine(1+). (-)-Synephrine has been reported in Mammillaria longimamma, Zanthoxylum fagara, and other organisms with relevant data. See also: (+)-Synephrine (note moved here).
p-Synephrine is an adrenergic receptor agonist with preferential binding to α-1 and β-3 adrenergic receptors. It is a naturally occurring phenethylamine alkaloid used in research on thermogenesis, lipolysis, and cardiovascular modulation. The compound suppresses LPS-induced acute lung injury by inhibiting the NF-κB signaling pathway. It has a molecular weight of 167.21 g/mol and formula C9H13NO2. The CAS number is 614-35-7. |
| Molecular Formula |
C9H13NO2
|
|---|---|
| Molecular Weight |
167.2
|
| Exact Mass |
167.095
|
| CAS # |
614-35-7
|
| Related CAS # |
5985-28-4 (HCl);16589-24-5 (tartrate);94-07-5 (racemate);614-35-7 (R-isomer);
|
| PubChem CID |
854067
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
165 °C(dec.)
|
| LogP |
1.035
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
12
|
| Complexity |
122
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CNC[C@@H](C1=CC=C(C=C1)O)O
|
| InChi Key |
YRCWQPVGYLYSOX-VIFPVBQESA-N
|
| InChi Code |
InChI=1S/C9H13NO2/c1-10-6-9(12)7-2-4-8(11)5-3-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1
|
| Chemical Name |
(R)-(-)-1-(4-Hydroxyphenyl)-2-(methylamino)ethanol
|
| Synonyms |
l-Sympatol Oxedrine ((-)-) (-)-Synephrine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~2 mg/mL (~11.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 5 mg/mL (29.90 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9809 mL | 29.9043 mL | 59.8086 mL | |
| 5 mM | 1.1962 mL | 5.9809 mL | 11.9617 mL | |
| 10 mM | 0.5981 mL | 2.9904 mL | 5.9809 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
